Efficacy and Safety of GNR-038 vs Berinert® in Patients With Hereditary Angioedema

NCT04898309 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Company pipeline revision

Conditions

Hereditary Angioedema

Interventions

DRUG: GNR-038, 50 МЕ/ kg
DRUG: GNR-038, 100 МЕ/ kg
DRUG: Berinert®, 20 МЕ/ kg
DRUG: Placebo
DRUG: GNR-038. The dose will be selected according to results of stage 1 clinical trial.
DRUG: Berinert®, 20 МЕ/ kg

Sponsor

AO GENERIUM